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esponsibility of InstAbstract DRDE-07, a newly synthesized amifostine analog currently under clinical investigation in a phase
I trial, is a potent antidote against sulfur mustard toxicity. The purpose of this research was to evaluate the
pharmacokinetic proﬁle of DRDE-07 in female Swiss Albino mice after a single oral dose of 400 or 600 mg/
kg. The physicochemical properties of DRDE-07, including solubility, pKa, Log P, plasma protein binding and
plasma/blood partitioning, were determined to support the pharmacokinetic characterization. DRDE-07
concentration was determined by an HPLC-UV method. The proﬁle of plasma concentration versus time
was analyzed using a non-compartmental model. Plasma protein binding was assessed using ultraﬁltration.
DRDE-07 appeared rapidly in plasma after oral administration with peak plasma levels (Cmax) observed in less
than 15 min. There was a rapid decline in the plasma levels followed by a smaller second peak about 90 min
after dosing. The plasma protein binding of DRDE-07 was found to be less than 25% at all concentrations
studied. Plasma clearance of DRDE-07 is expected to be 1.5 fold higher than the blood clearance of DRDE-
07. The probable metabolite of DRDE-07 was identiﬁed as phenyl-S-ethyl amine.
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Nerve agents and blistering agents continue to be a threat as
chemical warfare agents in spite of controls imposed by the
Chemical Weapon Convention (CWC). The CWC prohibits the
production, storage, transport and use of chemicals on enemy
forces1. One of such chemical is sulfur mustard (SM), commonly
known as mustard gas and included in the Schedule I of the CWC.
Reports are available of its use in several instances before the
CWC came into force2–4. In spite of the CWC, the threat exists
that SM will be used clandestinely during war or by terrorist
organizations because of its simple method of preparation. Despite
90 years of research, there is still no antidote for mustard. This fact
is especially crucial when we consider that probably at least a
dozen countries have SM in their arsenals today. Development of
an effective prophylactic or therapeutic antidote is an immediate
requirement for personnel and particularly for OPCW (Organiza-
tion for the Prohibition of Chemical Weapons) ofﬁcials engaged in
the destruction of SM.
Taking into consideration the increase in terrorist activities,
drug development against SM is needed not only for army
personnel but also for civilians. A large number of chemicals
and drugs including sulfur compounds have been tested against
SM or nitrogen mustard toxicity in various protocols but have been
found to have little or no protective effect against their systemic
toxicity5,6. There still no effective treatment for SM toxicity and it
poses a challenge even today7,8.
DRDE-07, an analog of amifostine, was found to be the most
potent agent against sulfur mustard toxicity. It has been proven
that orally administration of DRDE-07 is more efﬁcacious than
amifostine against percutaneously administered SM. DNA
damage, the decrease in body weight, and the depletion of GSH
induced by SM were signiﬁcantly protected by DRDE-07. Both
in vitro and in vivo data indicate promising roles of DRDE-07 as a
prophylactic agent against SM poisoning9–11. The physicochem-
ical properties of a drug determine its pharmacokinetic fate in the
body. Therefore, physicochemical data can be used to explain the
ADME proﬁle obtained in animal studies. Since DRDE-07 is a
new compound, preclinical characterization of DRDE-07 is
essential for further studies of this agent. Presently, there is no
detailed pre-clinical pharmacokinetic data of DRDE-07 in mice.
Hence, the purpose of this study was to determine the pharmaco-
kinetic proﬁle of DRDE-07 and to establish the solubility, pKa,
log P, plasma protein binding and red blood cell (RBC)/plasma
partitioning of DRDE-07, and to identify the possible metabolites
of DRDE-07 in mice.2. Materials and methods
2.1. Chemicals
DRDE-07 (Fig. 1) was developed in the synthetic chemistry labo-
ratory of the Defense Research and Development Establishment,Figure 1 Structure of DRDE-07 [(2-aminoethyl)(2-(phenylsulfanyl)
ethylamine].Gwalior, with its chemical structure conﬁrmed by 1H NMR, 13C
NMR, and high-resolution mass spectrometry. The HPLC purity of
DRDE-07 was greater than 99.5%. Heptane sulfonic acid (HSA),
tetra methyl ammonium chloride (TMAC), hydrochloric acid and
n-octanol were purchased from Aldrich (USA), while acetone,
ethyl acetate orthophophoric acid, sodium chloride, dibasic and
monobasic sodium hydrogen phosphate and dibasic and mono-
basic potassium hydrogen phosphate were purchased from Merck
(Germany). HPLC grade acetonitrile and methanol were obtained
from J.T. Baker (Philipsburg, NJ). Millipore water was prepared
via a Millipore puriﬁcation system (Milford, MA). All other
chemicals and reagents were of analytical/regent grade. Blood
was collected from healthy Swiss Albino mice in heparinized tubes
and was centrifuged to separate plasma so as to generate drug-free
mice plasma.
2.2. Bioanalysis
The DRDE-07 concentrations in mouse plasma and urine were
determined using an HPLC-UV method described in our previous
papers12,13. The least squares linear regression coefﬁcient of
determination (R2) was greater than 0.9998 and 0.9986 (minimum
value) in all analytical tests for plasma and urine analysis,
respectively. Details of accuracy, precision, recovery and stability
of DRDE-07 are shown in Table 112,13. Reverse-phased HPLC-UV
methods were used for the determination of DRDE-07 in samples.
The mobile phase consisting of (A) double-distilled H2O containing
10 mmol/L sodium dihydrogen phosphate, 0.5 mmol/L HSA and
1 mmol/L of TMAC (pH 3.5) and (B) acetonitrile was freshly made
daily and degassed before use. The mobile phase was delivered
isocratically in a ratio of 78% (A) and 22% (B) through a Waters X-
Tera, MS C18 column coupled with a Waters X-Tera, MS C18
guard column at 30 1C and a ﬂow rate of 1.0 mL/min. All samples
and standard solutions were detected at 249 nm where the maximum
absorbance of the substance investigated was observed.
2.3. Solubility
The aqueous solubility of DRDE-07 in simulated intestinal ﬂuid
(SIF) and simulated gastric ﬂuid (SGF) was measured using a
shaking ﬂask method14. DRDE-07 powder was weighed (50 mg)
in glass vial and SIF (pH 6.8) or SGF (pH 1.2) was added to
produce saturated solutions. Samples were prepared in triplicate.
Samples were placed for 24 h in a shaking water bath at 37 1C.
The samples were collected and ﬁltered through 0.22 μm ﬁlter.
The concentration of DRDE-07 in the diluted supernatant (SIF or
SGF) was determined using a Waters HPLC system.
2.4. Drug lipophilicity (Log P)
The octanol:water partition coefﬁcient, a measure of drug lipophi-
licity, was measured by established methods15–17. Phosphate
buffer (0.1 mol/L) was prepared from deionized water and dibasic
sodium phosphate. The pH was adjusted to 7.4 using 85%
phosphoric acid. This aqueous buffer solution was fortiﬁed with
DRDE-07 at 10, 25 and 50 μg/mL and added to an equal volume
of n-octanol in a screw top tube. The tube was gently rocked for
1 h at room temperature to equally disperse the drug into each
phase of the tube and then centrifuged for 10 min at 2000 rpm.
Before and after incubation and shaking, the drug concentration in
the aqueous layer was analyzed by HPLC. The partition coefﬁcient
Table 1 Accuracy, precision, recovery and stability of DRDE-07 in mice plasma and urinea.
Data item Spiked concentration in plasma (μg/mL) Spiked concentration in urine (μg/mL)
1 10 100 1 10 100
Accuracy and precision
Intra-day precision (n¼5)
Measured concentration (μg/mL) 1.00070.02 9.9870.17 95.5674.23 0.8470.04 9.5570.21 95.1271.17
Accuracy (%) 100.07 99.78 95.56 84.26 95.46 95.12
RSD (%) 2.15 1.75 4.38 4.16 2.24 1.23
Difference (%) 0.07 0.22 3.25 15.74 4.54 4.88
Inter-day precision (n¼5)
Measured concentration (μg/mL) 1.0170.02 9.5770.11 98.6773.16 0.8670.03 9.6270.09 94.4570.66
Accuracy (%) 101.02 95.69 98.67 85.48 96.16 94.45
RSD (%) 2.09 1.07 3.21 3.49 0.96 0.70
Difference (%) 1.02 4.31 1.33 14.52 3.84 5.55
Recovery (%) 96.8771.89 96.4371.41 88.2671.49 40.6670.83 65.0570.83 61.8471.11
Stability of samples (n¼3)
Freeze-thaw for three cycles (%) 93.1671.21 ND 95.1272.62 90.6672.07 ND 94.7872.27
Short-term (room temperature, 24 h)(%) 95.9173.76 ND 94.7672.73 93.7972.66 ND 96.0972.91
Long-term (20 1C, 30 days) (%) 92.1473.16 ND 96.0370.56 94.1271.77 ND 93.7271.50
aSD: standard deviation; RSD: relative standard deviation; ND: not determined.
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logarithm of partition coefﬁcient (PC).
PC¼ConcentrationPreincubationConcentrationPostincubation
ConcentrationPostincubation
ð1Þ
2.5. Plasma protein binding (PPB)
The plasma protein binding of DRDE-07 was estimated using the
ultra-ﬁltration method. Brieﬂy, freshly collected female mouse
plasma was spiked with DRDE-07 to obtain the plasma concen-
trations of 12.5, 25 and 50 μg/mL. The spiked plasma was allowed
to equilibrate at 37 1C for 60 min before the start of the study. The
separation of bound and unbound forms of DRDE-07 and
preparation of protein-free ﬁltrate were achieved by ﬁltration
through Amicon Ultra-4 centrifugal ﬁlters (molecular weight cut-
off: 3 kDa) from Millipore (Bedford, MA). Samples at each
concentration (1 mL, n¼3) were placed in Centrifree devices
and centrifuged at 3600 rpm for 15 min at 37 1C to collect
approximate 200 μL of the original volume of plasma as ultra-
ﬁltrate. The concentrations of in-vitro plasma samples and their
respective ultra-ﬁltrates were analyzed by an HPLC method12. Eq.
(2) was used to calculate the percent-bound drug from plasma
(Concplasma) and ultraﬁltrate (Concultraﬁltrate) concentrations. Before
conducting the plasma-protein binding experiments, the non-
speciﬁc binding ability of DRDE-07 to the ultraﬁltration device
membrane was investigated. Two aqueous concentrations of drug,
10 and 50 μg/mL, were prepared from a stock solution (1 mg/mL).
These samples (1 mL each) were then placed in ultraﬁltration
devices and centrifuged at 3600 rpm for 15 min. The concentra-
tions of DRDE-07 in the ultraﬁltrate and the remaining aqueous
solution (did not undergo ultraﬁltration and represent total con-
centration) were then analyzed by HPLC. Eq. (3) was used to
determine the unbound percentage, and thus the percentage of drug
bound to the ultraﬁltration device membrane was obtained.Bound ð%Þ ¼ConcentrationUltrafiltrate
ConcentrationPlasma
 100 ð2Þ
Unbound ð%Þ ¼ Peak areaUF
Peak areaTotal
 100 ð3Þ
2.6. Blood/plasma partitioning
The extent of blood cell partitioning of DRDE-07 was determined in
mice. DRDE-07 (1 mg/mL) in saline was added to mouse blood that
contained sodium heparin at a ratio of 1:50 to give a ﬁnal
concentration of 100 μg/mL. Samples were incubated at 37 1C for
30 min. Plasma samples were obtained by centrifuging aliquots of
heparinized blood samples. The blood or plasma samples (100 μL)
were then processed and analyzed according to a validated HPLC
method12. All experiments were performed in triplicate. The blood-
to-plasma partition ratio (CB/CP) of DRDE-07 was calculated from
the drug concentration in blood and plasma. Blood cell distribution
was calculated as CB, CP and hematocrit (HCT) using
18
Blood cell distribution %ð Þ ¼ 100 ½CBCPð1HCTÞ
CB
ð4Þ
For determination of HCT, heparinised whole blood (1.0 mL)
was taken in an hematocrit tube and centrifuged at 2000g for
30 min. The HCT for whole mouse blood was calculated by
using19
HCT¼Volume of packed cell
Total blood volume
ð5Þ
2.7. Prediction of pKa
The acid dissociation constant of DRDE-07 was determined by the
method described by Albert and Serjeant20. The method is based
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nated) to dissociated (deprotonated species) in a series of non-
absorbing buffer solutions. For this purpose, the absorption spectra
of the molecular species were obtained ﬁrst in a buffer solution at
the pH in which the compound of interest would be present wholly
in either form. 30 μL of DRDE-07 stock solution (1 mg/mL) was
diluted to 3 mL in a cuvette containing either 0.1 mol/L hydro-
chloric acid or 0.1 mol/L sodium hydroxide solution and the
absorption spectrum of DRDE-07 in acid or alkali were deter-
mined over the wavelength 200–400 nm with a reference to blank
solution at 2571 1C. The spectra obtained in acid or alkali were of
protonated (Dm) and deprotonated (Di) molecules. Nine different
pH values, ranging from 5.2 to 6.8, were selected to determine the
pKa of DRDE-07. For this, appropriate buffer consisting of
phosphate (pH 5.2–6.8) was used to determine the dissociation
constants of DRDE-07. 30 μL of DRDE-07 stock solution (1 mg/mL)
was diluted to 3 mL in each buffer and the optical densities
were determined at analytical wavelengths using buffer blank at
2571 1C. A set of 9 values of pKa were obtained using
pKa ¼ pH þ log
DiD
DDm
ð6Þ
where Dm and Di correspond to the optical density of protonated
and deprotonated forms of DRDE-07, and D is the optical density
in the buffer. The average of the 9 measurements was considered
the pKa of the DRDE-07. A Shimadzu UV-1800 UV–visible
double-beam spectrophotometer with quartz cells of 10 mm was
used for spectrometric analysis. pH values of buffers were
determined using pH/ion selective meter (Model 1112000, Thermo
Scientiﬁc; USA). The pH meter was calibrated at 25 1C using a
two-point calibration method with commercially available standard
buffer solutions pH 4.0 and 7.0.Figure 2 HPLC chromatograms of blank plasma and plasma after
oral dosing of DRDE-07 (400 mg/kg).2.8. Pharmacokinetic study
Swiss Albino female mice were used in this study because DRDE-
07 offered better protection against SM in female mice11. All
animals weighed 25–30 g were obtained from the laboratory
division of the Defense Research and Development Establishment,
Gwalior, and were used for in vivo pharmacokinetic experiments.
All protocols were approved by the Animal Ethics Committee of
DRDE, Gwalior, India. The animals were individually housed in a
temperature-controlled room with 12 h light/dark cycle for at least
48 h before the experiment. A total of 44 mice were used for each
independent experiment (per dose). DRDE-07 was dissolved in
sterile saline (0.9% NaCl) and was administered orally at two
doses level 400 and 600 mg/kg, to the 2 h fasted mice using a mice
feeding needle and syringe. Blood samples were collected at 5, 15,
30, 60, 90, 120, 240, 360, 480, 720, and 1440 min via retroorbital
sinus puncture from the standard heparinized micro-hematocrit
capillary tubes into heparinized 0.5-mL centrifuge tubes, (typically
300 μL is collected from each animal, 4 animals per each time
point). The care was taken to minimize the trauma due to pain
during blood sampling by the use of appropriate diethyl ether
anesthesia. Blood samples were promptly centrifuged at 4000 rpm
for 10 min. Plasma samples were and stored at 20 1C and
analyzed using a validated HPLC method12. The pharmacokinetic
characterization of DRDE-07 was analyzed using PK Solver,
Version 2.021 and non-compartmental modeling (NCA) was
carried out according to conventional pharmacokinetic principles.2.9. Metabolite identiﬁcation
The HPLC chromatogram of plasma obtained after p.o. dosing of
DRDE-07 showed an extra peak along with the DRDE-07 peak,
which was not present in the HPLC chromatogram of blank
plasma (Fig. 2). This extra peak may be because of the presence of
one of the metabolites (M1) of the DRDE-07. To identify this
metabolite the HPLC fractions with the metabolite peak were
collected and analyzed by mass spectrometry.
2.9.1. Fraction collection
Liquid chromatographic separation was performed Waters HPLC
system equipped with Waters 2996 photodiode array detector
(PDA). The mobile phase12 used for quantifying the DRDE-07 in
plasma and urine contain phosphates and organic acid which are
not suitable for mass analysis, and therefore a different mobile
phase was used to collect the metabolite fractions. The mobile
phase consisted of (A) DD-H2O containing 0.2% v/v triﬂuroacetic
acid and (B) acetonitrile, and was delivered isocratically in a ratio
of 75% (A) and 22% (B) through a Waters X-Tera, C18 column at
30 1C and a ﬂow rate of 1.0 mL/min. This mobile phase was not
suitable to quantify the DRDE-07 in plasma because overlapping
peaks of DRDE-07 and blank plasma protein were observed at the
same retention time. Several metabolite fractions of DRDE-07
(M1) were collected manually using the above-described isocratic
program. The fractions of pure metabolite (M1) were combined
and evaporated to dryness using a Heto Vacuum Centrifuge, Maxi-
Dry Plus type.
2.9.2. Mass analysis
Chromatographic separation of the metabolite fractions (M1) was
carried out with Thermo Electron HPLC with surveyor LC pump
(San Jose, CA, USA) equipped with Thermo Electron Hypercarb,
100 mm 2.1 mm microbore column. The following solvent
composition was made for sample introduction: solvent A
(20 mmol/L ammonium hydroxide in water) and solvent B
(methanol). The pH of solvent A was adjusted to 8 by adding
25% solution of ammonia hydroxide. The same amount of
ammonium hydroxide was added to solvent B. Chromatographic
separations were performed using 90% B and 10% A at a ﬂow rate
of 200 μL/min. Column temperature was kept at 30 1C. Samples
were injected through a Rheodyne injector (Model 7010) ﬁtted
with 2 μL loop. The LC system was coupled on-line to a LCQ
Advantage ion trap spectrometer (Thermo Electron Corporation)
equipped with an orthogonal electrospray interface. The system
was operated in a positive ion mode. Helium was continually
ﬂowing into the collision cell at a pressure of 0.1 Pa during
the electrospray ionization tandem-mass spectrometry (ESI-MSn)
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m/z 50–300 amu. MSn spectra were obtained at the collision
energy of 30 eV.Table 3 Protein binding data analysis for mice plasmaa.
Nominal
concentration (μg/mL)
Unbound concentration
(μg/mL)
Bound (%)
12.5 9.7770.46 21.8274.66
25 18.8670.09 24.5470.37
50 39.0370.85 21.9471.69
aData based on an average of 3 replicate trials, presented as
average7SD.3. Results
3.1. Aqueous solubility in simulated intestinal/gastric ﬂuid
Good linearity between the peak areas to the aqueous DRDE-07
concentrations ranging from 1.0 to 100 μg/mL was obtained. The
linear regression correlation coefﬁcient (R2) was 0.9997. The
aqueous solubility, as determined by the mean value of DRDE-
07 concentrations at equilibrium, was found to be 0.98570.04
g/mL (n¼3) and 0.74770.03 g/mL (n¼3) in SIF and SGF,
respectively.
3.2. Lipophilicity
The average octanol:water partition coefﬁcient at concentrations of
10, 25 and 50 μg/mL was 0.2570.01. This is equivalent to a
logarithm of the partition coefﬁcient (log P) of 0.6 (Table 2).
3.3. Plasma protein binding
In the assay of plasma ﬁltrate, the peak-area of DRDE-07 showed
a linear relationship with the nominal concentrations of DRDE-07
in the tested range of 2.5–100 mg/mL. The linear regression
correlation coefﬁcient (R2) was 0.9974. There was no binding of
DRDE-07 to the ultraﬁltration device membrane; therefore the
method is considered suitable for use in the protein binding
studies. These results (Table 3) show DRDE-07 binding to mouse
plasma proteins (21.82%–24.54%). The fraction of plasma protein
binding of DRDE-07 was found to be less than 25% at all
concentrations studied.
3.4. Blood/plasma partitioning
The extent of blood partitioning of DRDE-07 was measured in
mouse blood at a concentration of 100 μg/mL at 37 1C. The blood
to plasma partition ratio (CB/CP) of DRDE-07 was found to be
1.5270.09. The HCT value was found to be 0.448 in mice and the
percent distribution of DRDE-07 in blood cells was found to be
18.7472.31, suggesting that DRDE-07 distributed primarily into
the blood compartment (Table 4). The plasma clearance is more
widely used in pharmacokinetics than the blood clearance owing
to sample collection and analysis are easier in plasma than in
blood. However, the clearance estimates of an organ (e.g., liver)
are generally described by blood clearance. The relationships
between blood clearance (CLb) and plasma clearance (CLp) can beTable 2 Calculation of Log P.
Nominal concentration (μg/mL) Pre-incubation concentration (μg/mL)
10 10.2270.40
25 23.2570.43
50 50.8671.27
Average
Data based on an average of 3 replicate trials, presented as average7SD.described by22
CLb ¼
dA=dt
CBðtÞ
and CLp ¼
dA=dt
CPðtÞ
ð7Þ
Therefore, the blood versus plasma concentration ratio can be
used to represent the ratio of plasma clearance versus blood
clearance as
CB
Cp
¼ CLP
CLB
ð8Þ
DRDE-07 was found to be distributed mostly into the blood
than rather the plasma. Hence, the plasma clearance of DRDE-07
is expected to be about 1.5-fold higher than the blood clearance of
DRDE-07.
3.5. pKa
DRDE-07, a nitrogen-containing drug, is generally regarded as a
basic drug. In this study, the pKa value of DRDE-07 was predicted
by a spectrophotometric method. Although a conventional titration
method can be used for experimental measurement of the pKa.
Table 5 contains the pH and absorbance data. The average pKa
value of DRDE-07 was found to be 5.9570.28.
3.6. Pharmacokinetic study
The concentration–time proﬁles of DRDE-07 after oral (400 and
600 mg/kg) administration are shown in Fig. 3. Following oral
administration (400 and 600 mg/kg) the compound exhibited two
peak plasma concentrations. Cmax,1 (9.8874.31 and 22.3974.52,
respectively) was observed at 15 min, while Cmax,2 (4.3970.87
and 10.7774.10, respectively) was observed at 90 min but was
lower than Cmax,1. Pharmacokinetic parameters obtained from non-
compartmental analysis of oral plasma levels of DRDE-07 in mice
are summarized in Table 6. The systemic plasma clearance (CL/F)
was 320.10 and 192.21 mL/min/kg after 400 and 600 mg/kg
oral doses respectively. The volume of distribution (Vz/F) was
found as 213.73 and 102.50 L/kg after 400 and 600 mg/kg oral
doses, respectively, which is greater than the total body water.Post-incubation concentration (μg/mL) PC Log P
8.3070.09 0.2370.04 0.6070.08
18.8870.07 0.2470.02 0.6070.03
39.4171.39 0.2670.03 0.5970.05
0.2570.01 0.6070.01
Table 4 Blood/plasma partitioning data analysis for micea.
Nominal concentration
(μg/mL)
Drug concentration in plasma
(μg/mL)
Drug concentration in blood
(μg/mL)
CB/CP Blood cell distribution (%)
100 36.2772.51 54.8970.88 1.5270.09 18.7472.31
aData based on an average of 3 replicate trials, presented as average7SD.
Table 5 Calculation of pKa from absorbance data at
various pH.
pH Absorbance (d) pKa¼pHþlog[(DiD)/(DDm)]
5.2 0.22725 5.511648
5.4 0.22935 5.633931
5.6 0.23210 5.737252
5.8 0.23368 5.883337
6.0 0.23628 5.995804
6.2 0.23903 6.10309
6.4 0.24045 6.254476
6.6 0.24620 6.244145
6.8 0.26318 6.223706
pKa 5.9570.28
Dm¼0.21028 (in 0.1 mol/L HCl); Di¼0.26203 (in 0.1 mol/L
NaOH).
Figure 3 Mean concentration–time curve in mice after a single p.o.
doses of DRDE-07 (400 and 600 mg/kg). Each point represents the
plasma concentration (mean7SD) for 4 animals.
Table 6 Pharmacokinetic parameters of DRDE-07 in mice
calculated non-compartmental analysis after oral administration.
Parameter 400 mg/kg 600 mg/kg
Cmax,1 (μg/mL) 9.8874.31 22.3974.52
Cmax,2 (μg/mL) 4.3970.87 10.7774.10
Tmax,1 (min) 15 15
Tmax,2 (min) 90 90
λz (min
1) 0.0015 0.0019
t1/2 (h) 7.7 6.16
Tlag (min) 0 0
Clast/Cmax 0.02 0.03
AUC0–t (μg min/mL) 1113.66 2762.99
AUC0–1 (μg min/mL) 1249.61 3121.52
AUC0–t/0–1 0.891 0.885
AUMC0–1 (μg min2/mL) 635,805.41 1,682,825.74
MRT0–1 (h) 8.48 8.99
Vz/F (L/kg) 213.73 102.49
CL/F (mL/min/kg) 320.099 192.214
Pharmokinetic proﬁle of DRDE-07 399The estimated terminal half-life was 7.7 and 6.16 h and MRT was
8.48 and 8.99 h after 400 and 600 mg/kg oral doses respectively.Figure 4 LC–MS spectrum of DRDE-07.3.7. Metabolite identiﬁcation
The metabolite identiﬁcation was conducted by comparing the LC/
MS chromatogram of the metabolite fraction with that of the
expected metabolite i.e. phenyl-S-ethyl amine and standard
DRDE-07 samples (Figs. 4, 5 and 6). The metabolite, M1, was
a result of cleavage of the ethylene amine moiety, most probably
in the form of aziridine from DRDE-07 because the observed
(MþH)þ ion (154 Da) was 43 Da lower than DRDE-07 (197 Da).
The LC/MS spectrum of the DRDE-07 metabolite resembled the
ESI-MS/MS spectrum of phenyl-S-ethyl amine indicating that the
probable metabolite of DRDE-07 may be phenyl-S-ethyl amine.The proposed MS/MS fragments of DRDE-07 and its metabolite
are shown in Table 7 and Fig. 7.4. Discussion
Preclinical pharmacokinetic studies aid in the determination and
optimization of various therapy-related parameters, including the
dosing, frequency of administration, formulation, and potential
sites of toxicity of the agent. Such information is essential to the
Figure 5 LC–MS spectrum of metabolite (M1).
Figure 6 ESI-MS/MS spectrum of pheny-S-ethylamine (M1).
Table 7 LC/MS/MS analysis of metabolites of DRDE-07.
Sample Molecular
weight
[MþH]þ MS/MS
fragment
DRDE-07 196 197 137, 180
Metabolite (M1) 153 154 137
Phenyl-S-ethyl
amine
153 154 137
Figure 7 Proposed fragmentations of (A) DRDE-07 and (B) metabolite,
M1.
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good SIG and SGF solubility of DRDE07 contributes to the
favorable oral absorption and will also make this drug amenable to
compounding in various aqueous formulations. It also presented a
relatively low octanol:water partition coefﬁcient (0.6) which
indicates its passage through the epithelium via paracellular
channels. DRDE-07 was found to be distributed mostly into the
blood than rather the plasma. Hence, the plasma clearance of
DRDE-07 is expected to be about 1.5 fold higher than the blood
clearance of DRDE-07. At oral doses, the kinetics of DRDE-07appears to show no dose-proportionality. Nevertheless, Cmax and
AUC did not increase proportionally with the dose, indicating that
DRDE-07 follows non-linear kinetics in mice. As Cmax is
dependent on the absorption of the compound, thus no co-
relation was found between the ratio of the dose administered
and the Cmax. DRDE-07 showed low binding to proteins in mice
plasma (o25%), which may result in a much higher clearance that
favors the extensive ﬁrst-pass effect, resulting in low bioavail-
ability. Low plasma-protein binding also leads to less DRDE-07
being present in the central blood compartment and better
extracellular penetration, thus contributing a higher volume of
distribution. DRDE-07 appeared rapidly in plasma after oral
administration with peak plasma levels (Cmax) observed in less
than 15 min after administration; afterwards there was a rapid
decline in the plasma levels followed by a smaller second peak
about 90 min after the dose administration. The possibility of
enterohepatic recirculation of the compound or erratic absorption
was indicated by the presence of the second peak in the proﬁle
after oral administration. The volume of distribution (Vz/F) was
found to be much larger than the blood volume of mice, indicating
rapid uptake of the compound by quickly perfused organs viz, liver
and kidney. A double-peak phenomenon was observed in four out
of total four animals receiving the 200 and 600 mg/kg oral dose,
which implies that the DRDE-07 and/or its conjugated metabolites
may be excreted into the bile, undergo hydrolysis in the gut (if a
conjugated metabolite exists), and be reabsorbed into systemic
circulation23. The LC/MS spectrum of the DRDE-07 metabolite
resembled the ESI-MS/MS spectrum of phenyl-S-ethyl amine,
indicating that the probable metabolite of DRDE-07 may be
phenyl-S-ethyl amine. The results obtained from this study should
prove useful for further research of DRDE-07.References
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